Jun 21, 2019
Sangamo Announces Upcoming Presentation Of Investigational SB-525 Hemophilia A Gene Therapy Data At ISTH 2019
May 15, 2019
Sangamo Therapeutics Announces Presentations At Upcoming Scientific, Medical And Investor Conferences
May 10, 2019
Sangamo Therapeutics Announces Participation In The Bank Of America Merrill Lynch 2019 Health Care Conference
May 01, 2019
Sangamo Therapeutics Announces First Quarter 2019 Conference Call And Webcast
Apr 08, 2019
Sangamo Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
Apr 04, 2019
Sangamo Therapeutics Announces Pricing of Public Offering of Common Stock
Apr 03, 2019
Sangamo Therapeutics Announces Proposed Public Offering of Common Stock
Apr 02, 2019
Sangamo Announces Agreement Securing Access To Large-Scale, Commercial-Grade Manufacturing Capacity At Brammer Bio
Apr 02, 2019
Sangamo Provides Clinical Development Update Including Early Phase 1/2 Beta Thalassemia Gene-edited Cell Therapy Data
Apr 01, 2019
Sangamo Therapeutics To Host April 2, 2019 Conference Call To Provide Clinical Update
Mar 29, 2019
Sangamo Therapeutics Presents New Preclinical Data Demonstrating Significant Reduction In Tau Expression With Gene Regulation Technology
Mar 08, 2019
Sangamo Therapeutics Announces Publication Of Data Demonstrating New Zinc Finger Nuclease Architectures Enabling High-Precision Genome Editing
Mar 06, 2019
Sangamo Therapeutics Announces Participation At Upcoming Investor Conferences
Feb 28, 2019
Sangamo Therapeutics Reports Fourth Quarter And Full Year 2018 Financial Results
Feb 21, 2019
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2018 Conference Call and Webcast
Feb 20, 2019
Sangamo Announces FDA Acceptance of IND Application for ST-920 Gene Therapy Candidate for Fabry Disease
Feb 07, 2019
Sangamo Announces Interim Results Of Phase 1/2 CHAMPIONS Study Showing Preliminary Evidence Of In Vivo Genome Editing In Patients With MPS II Treated With SB-913
Feb 07, 2019
Sangamo Announces Interim Results Of Phase 1/2 EMPOWERS Study Evaluating SB-318 Zinc Finger Nuclease (ZFN) In Vivo Genome Editing Demonstrating Increased Leukocyte IDUA Activity In Patients With MPS I
Feb 01, 2019
Sangamo Therapeutics To Host Conference Call To Review Interim Results From Phase 1/2 CHAMPIONS And EMPOWERS Studies For MPS II And MPS I
Jan 22, 2019
Sangamo Therapeutics Appoints Adrian Woolfson, BM., B.Ch., Ph.D., As Executive Vice President Of Research And Development